We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sanofi Sa | LSE:0A2V | London | Ordinary Share | SANOFI ADR REP 1 1/2 ORD (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Health & Allied Services,nec | 43.07B | 5.4B | 4.2694 | 23.17 | 0 |
TIDMTTM TIDM0A2V
RNS Number : 9572I
Capital Group Companies Inc
07 December 2022
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION Name of person dealing The Capital Group Companies, Inc. Company dealt in Horizon Therapeutics PLC ----------------------------------------------- Class of relevant security to which US$0.0001 ordinary shares (IE00BQPVQZ61) the dealings being disclosed relate ----------------------------------------------- Date of dealing 06 December 2022 ----------------------------------------------- 2. INTERESTS AND SHORT POSITIONS (a) Interests and short positions (following dealing) in the class of relevant security dealt in Long Short Number (%) Number (%) --------------------- ---------- ------------- ----------- (1) Relevant securities 10,076,506 shares 4.45 % --------------------- ---------- ------------- ----------- (2) Derivatives (other than options): ---- ---------------------------- --------------------- ---------- ------------- ----------- (3) Options and agreements to purchase/sell: ---- ---------------------------- --------------------- ---------- ------------- ----------- Total 10,076,506 shares 4.45 % ---- ---------------------------- --------------------- ---------- ------------- ----------- (b) Interests and short positions in relevant securities of the company, other than the class dealt in Class of relevant security: Long Short Number (%) Number (%) --------------------- ---------- ------------- ----------- (1) Relevant securities ---- ---------------------------- --------------------- ---------- ------------- ----------- (2) Derivatives (other than options): ---- ---------------------------- --------------------- ---------- ------------- ----------- (3) Options and agreements to purchase/sell: ---- ---------------------------- --------------------- ---------- ------------- ----------- Total ---- ---------------------------- --------------------- ---------- ------------- ----------- 3. DEALINGS (a) Purchases and sales Purchase/sale Number of relevant Price per unit securities Purchase 112 shares 96.8500 - USD ------------------------------------ ---------------------------- Purchase 79 shares 98.4800 - USD ------------------------------------ ---------------------------- There was a Transfer In of 52 shares of US$0.0001 ordinary shares (b) Derivatives transactions (other than options transactions) Product name Nature of transaction Number of relevant Price per unit e.g. CFD securities (c) Options transactions in respect of existing relevant securities (i) Writing, selling, purchasing or varying Product name Writing, Number of Exercise Type, Expiry Option money e.g. call option purchasing, securities price e.g. American, date paid/ received selling, to which European per unit varying the option etc. etc. relates (ii) Exercising Product name Number of securities Exercise price per unit e.g. call option (d) Other dealings (including subscribing for new securities) Nature of transaction Details Price per unit (if applicable) 4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. None Is a Supplemental Form 8 attached? NO Date of disclosure 07 December 2022 Contact name Brandon Tuley -------------------------------- Telephone number 213 615 0469 -------------------------------- If a connected EFM, name of offeree/offeror with which connected -------------------------------- If a connected EFM, state nature of connection --------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ISEBKOBPQBDDCBK
(END) Dow Jones Newswires
December 07, 2022 10:01 ET (15:01 GMT)
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions